


AMENDMENTS TO THE CLAIMS

This Listing of Claims will replace all prior versions, including listings, of claims in the application.

Listing of Claims

Claim 1 (previously presented): A method of inhibiting overactivity of phagocytes or lymphocytes in an individual by administering to said individual an effective amount of a lignan, wherein said lignan has the formula



wherein R is H or OH when R₁ is OCH₃ and R₂ is OH or R is H when R₁ is OH and R₂ is H,
wherein said lignan is hydroxymatairesinol when R is OH, R₁ is OCH₃ and R₂ is OH, or is
matairesinol when R is H, R₁ is OCH₃ and R₂ is OH or is enterolactone when R is H, R₁ is OH and
R₂ is H, and
wherein

i) the phagocytes are neutrophils and the lignan is hydroxymatairesinol or matairesinol or a mixture thereof, or

ii) the phagocytes are cells of myeloid origin and the lignan is enterolactone or hydroxymatairesinol or a mixture thereof, or

iii) the lymphocytes are T-lymphocytes and the lignan is hydroxymatairesinol, matairesinol or enterolactone or a mixture thereof.

Claim 2 (original): The method according to claim 1, wherein the phagocytes are neutrophils and the lignan is hydroxymatairesinol or matairesinol or a mixture thereof.

Claim 3 (original): The method according to claim 1, wherein the phagocytes are cells of myeloid origin and the lignan is enterolactone or hydroxymatairesinol or a mixture thereof.

Claim 4 (original): The method according to claim 1, wherein the lymphocytes are T-lymphocytes and the lignan is hydroxymatairesinol, matairesinol or enterolactone or a mixture thereof.

Claim 5 (original): The method according to claim 2, wherein oxidative burst caused by stimulus of the neutrophils is decreased.

Claim 6 (original): The method according to claim 2, wherein the myeloperoxidase activity in converting the reactive oxygen species, released by oxidative burst caused by stimulus of said neutrophils, is decreased.

Claims 7-16 (canceled).

Application No.: 09/991,971
Amendment Dated 19 March 2004
Reply to Office Action of 19 December 2003

Claim 17 (previously presented): The method according to claim 1, wherein said lignan is hydroxymatairesinol or a mixture of hydroxymatairesinol and matairesinol.

Claim 18 (previously presented): The method according to claim 1, wherein said lignan is hydroxymatairesinol or a mixture of hydroxymatairesinol and enterolactone.

Claims 19-20 (canceled).